Navigation Links
Neuroblastoma: Autophagy protects from chemotherapy
Date:7/1/2013

Neuroblastomas are pediatric tumors that originate from cells of the embryonic nervous system. The disease can take widely varying clinical courses that range from spontaneous regression to fatal outcomes. Highly aggressive neuroblastomas rarely respond well to chemotherapy. Understanding and overcoming the resistance mechanisms of highly aggressive neuroblastomas are considered essential to the development of effective treatments.

Scientists from the department headed by Professor Dr. Olaf Witt at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and at Heidelberg University Hospital are searching for more effective methods to treat neuroblastomas. The researchers are particularly focusing on the role of 18 different HDAC enzymes which appear to promote the aggressiveness of neuroblastomas in various ways. Dr. Ina Oehme and her colleagues from Witt's department have now studied whether a member of the HDAC family might be linked to the sensitivity of tumors to chemotherapy in high-risk neuroblastomas. She discovered that the high-risk tumors that responded well to therapy were those which had produced only small quantities of HDAC10 prior to treatment.

The Heidelberg researchers subsequently used an experimental agent or a method of blocking the gene to turn off HDAC10 experimentally in cell cultures developed from highly aggressive neuroblastomas. They subsequently treated the cells with the chemotherapy agent doxorubicin. In neuroblastoma cells, this treatment normally induces a self-digestion process known as autophagy, a kind of recycling of endogenous cellular components. This is a biologically ancient program for survival that protects cells during starvation. Highly aggressive cancer cells use autophagy to overcome stress caused by cytotoxic agents.

However, in neuroblastoma cells without a functioning form of HDAC10, treatment disrupted the multi-stage process of autophagy of cellular components at
'/>"/>

Contact: Dr. Sibylle Kohlstädt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Page: 1 2

Related biology news :

1. Parkinsons disease: Parkin protects from neuronal cell death
2. Biodiversity protects against disease, scientists find
3. New park protects 15,000 gorillas
4. Ah, that new car smell: NASA technology protects spacecraft from outgassed molecular contaminants
5. A class of RNA molecules protects germ cells from damage, Penn vet researchers show
6. Strawberry extract protects against UVA rays
7. UN protects wild heart of Central Africa
8. Boosting blood system protein complex protects against radiation toxicity
9. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
10. Discovery may help prevent chemotherapy-induced anemia
11. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
(Date:11/3/2014)... -- Research and Markets has announced the addition ... and Companies" to their offering. This ... have already started to play an important role in the ... old fashioned bone marrow transplants. Role of cells in drug ... a part of medical practice. Stem cells are ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2
... lobe dementia ,Frontal lobe dementia (Frontotemporal Dementia, FTD) ... is the form of dementia that occurs most frequently in ... in the frontal lobe where large numbers of brain cells ... part of the brain and constitutes about 30% of the ...
... J. Craig Venter, Energy Bioscience Institute,s Chris Somerville ... Department of Energy Joint Genome Institute (DOE JGI) ... March 25-27, 2009 in Walnut Creek, Calif. ... of renewable energy strategies, biomass conversion to biofuels, ...
... GAINESVILLE, Fla. Older, active people who have a drink ... according to a report today from a University of Florida ... and Drugs . Although people 50 or older in ... they performed worse on special tests after having moderate amounts ...
Cached Biology News:Blood test predicts chance of dementia 2Venter, Somerville and Church highlight DOE/JGI genomics of energy and environment meeting 2After a few drinks, older adults more impaired than they think 2After a few drinks, older adults more impaired than they think 3
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori Therapeutics ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com ... 4, 2014 TIME:    11:15 am PT / 2:15 ... this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... time and receive event updates. This will ...
(Date:11/18/2014)... SAN BRUNO, Calif. , Nov. 18, 2014 ... is a platinum sponsor of the 10th Annual World Stem ... and regenerative medicine stakeholders. The 2014 World Stem Cell Summit ... San Antonio, Texas . ... the discovery and development of lifesaving cures and therapies, convening ...
(Date:11/18/2014)... 17, 2014 Cirrascale Corporation ... blade-based and rackmount computing infrastructure, today announced it ... accelerator throughout its GPU-enabled blade server and high-performance ... company’s latest proprietary 80-lane Gen3 PCIe switch-enabled risers, ... Tesla K80 dual-GPU accelerator cards in a single ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... 12 Odyssey Thera, Inc.,announced today that the ... No. 7,306,914, entitled "Protein-fragment Complementation,Assays (PCA) in whole ... infectious disease and gene therapy." This is the,twelfth ... The patent describes a method for detecting protein-protein,interactions ...
... "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of ... First Modules due Before ... ARPN) announced today the enrolment and dosing of the first ... the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) / healthcare-associated ...
... (Nasdaq:,INSM), today announced that it has been awarded ... (MDA). The grant is expected to cover a,substantial ... 24-week,Phase 3 enabling trial in patients with Myotonic ... biopharmaceutical company with extensive,expertise in biologics and orphan ...
Cached Biology Technology:Odyssey Thera Granted U.S. Patent for Animal Imaging 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5Insmed Awarded $2.1 Million by Muscular Dystrophy Association 2Insmed Awarded $2.1 Million by Muscular Dystrophy Association 3
... 48° Fixed Angle Polypropylene Rotor ... Series, IEC Centra CL3/CL3R** and Centra-MP4/MP4R*. ... quiet operation. /MP4, ,EXCLUSIVE polypropylene rotor ... can be repeatedly autoclaved. Polypropylene ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
... The Xcise is a powerful technology ... throughput proteome analysis. High quality sample ... untrained user. , The Xcise is a ... for high throughput proteome analysis. It combines ...
Extra Large bottle for hybridization 300 x 70mm...
Biology Products: